Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 626 to 650 of 921

TitleReference numberPublishedLast updated
Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancerTA503
Lenvatinib with everolimus for previously treated advanced renal cell carcinomaTA498
Glecaprevir–pibrentasvir for treating chronic hepatitis CTA499
Ceritinib for untreated ALK-positive non-small-cell lung cancerTA500
Golimumab for treating active non-radiographic axial spondyloarthritisTA497
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA495
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancerTA496
Naltrexone–bupropion for managing overweight and obesityTA494
Vismodegib for treating basal cell carcinomaTA489
Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxaneTA458
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumoursTA488
Sarilumab for moderate to severe rheumatoid arthritisTA485
Aflibercept for treating choroidal neovascularisationTA486
Tofacitinib for moderate to severe rheumatoid arthritisTA480
Immunosuppressive therapy for kidney transplant in adultsTA481
Immunosuppressive therapy for kidney transplant in children and young peopleTA482
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the kneeTA477
Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphomaTA478
Reslizumab for treating severe eosinophilic asthmaTA479
Cetuximab and panitumumab for previously untreated metastatic colorectal cancerTA439
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pembrolizumab for advanced melanoma not previously treated with ipilimumabTA366
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumabTA357
Sorafenib for treating advanced hepatocellular carcinomaTA474
Dimethyl fumarate for treating moderate to severe plaque psoriasisTA475

Results per page

  1. 10
  2. 25
  3. 50
  4. All